Navigation Links
Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimer's Disease in Second Quarter of 2008
Date:1/28/2008

- Conference Call Today at 4:30 p.m. Eastern Time -

SAN FRANCISCO, Jan. 28 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that, based on its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), the Company plans to begin a pivotal confirmatory Phase 3 trial of Dimebon(TM) for mild-to-moderate Alzheimer's Disease in the second quarter of 2008.

The FDA informed Medivation that the company's previously completed trial conducted in Russia can be used as one of the two pivotal studies required to support the approval of Dimebon to treat mild-to-moderate Alzheimer's disease, as long as a significant proportion of the sites in the confirmatory Phase 3 trial are located in the United States.

"We are now a Phase 3 company with clear regulatory guidance on the pivotal trials required to seek marketing approval for Dimebon in the United States," said David T. Hung, M.D., president and chief executive officer of Medivation. "This is a significant step forward for Medivation, and validates our strategy to advance Dimebon directly into a pivotal Phase 3 trial."

The Phase 3 clinical trial will enroll approximately 525 patients with mild-to-moderate Alzheimer's disease at sites in the United States, Europe and South America. Patients will be randomized to one of three treatment groups: Dimebon 20 mg three times per day (TID); Dimebon 5 mg TID; and placebo. Patients will be treated for six months and may not be taking any other Alzheimer's disease drugs. The primary endpoints are the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) and the Clinician's Interview-Based Impression of Change plus caregiver interview (CIBIC-plus).

In the previously completed trial Dimebon-treated patients were significantly improved over placebo patients on both the ADAS-cog and CIBIC-plus, with p values of less than 0.0001. This level of statistical significance is several times better than what is required to obtain marketing approval.

"We changed as little as possible in the design of the Phase 3 trial given the highly statistically significant results of our previous trial," said Lynn Seely, M.D., chief medical officer of Medivation. "The primary endpoints, duration of treatment and patient inclusion and exclusion criteria are all substantially identical to the previous trial. The primary differences are that the Phase 3 trial will be global and will test two doses of Dimebon -- the dose studied in the previous trial plus a lower dose to address the regulatory recommendation that minimum effective dose be explored in the development of investigational drugs."

Medivation expects to complete the pivotal confirmatory Phase 3 trial and apply for marketing approval in 2010.

Conference Call Details

To access the live conference call today at 4:30 p.m. Eastern Time via phone, please dial 877-627-6590 from the United States and Canada or +1-719-325-4868 internationally. Please dial in approximately 10 minutes prior to the start of the call. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com and clicking on the "Investor Relations" section. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Furthermore, as is typically the case at this stage of the regulatory review process, the FDA has not yet performed an in-depth review of Medivation's preclinical and clinical data, so its views remain subject to change. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include information about additional factors that could affect the Company's financial and operating results.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Health Plans Increase Use of Health Incentives
3. Area Health Care Providers Announce Plans to Integrate Services
4. EDAP Launches Enhanced Communication Plans at SIU Paris Congress
5. National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline
6. Precedent Launches Revolutionary Individual Health Insurance Plans in Texas
7. AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States
8. CEO Addresses Tennessee Business Leaders About Developing Pandemic and Business Continuity Plans
9. Delta Dental Plans Association Forms National Scientific Advisory Committee
10. Health Care Service Corporation Provides Personal Clinical Summaries to Members of its Blue Cross and Blue Shield plans in Illinois, New Mexico, Oklahoma and Texas
11. Massachusetts Employers and Health Plans Continue to Support Quality Care by Rewarding Physicians through Bridges to Excellence Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Santa Rosa, CA (PRWEB) , ... January 24, 2017 , ... ... rates is good news for everyone and particularly good news for prostate cancer patients: ... from the diagnosis. , According to the report the cancer death rate has dropped ...
(Date:1/24/2017)... ... 2017 , ... A yellow fever outbreak in Brazil has infected over 100 ... primarily spread through contact with infected mosquitos. The outbreak has sparked increased concern about ... , According to multiple health organizations, the best way to prevent yellow fever is ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... for everyday use to improve the connection with God. “Spiritual Vitamins: A Spiritual ... author. , Published by Christian Faith Publishing, Mathai Yohannan’s new book engages the ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... ... refined coffee house-caliber protein and espresso drink, announced its CLICK® Coffee Protein Drink ... , CLICK® Coffee Protein Drink Mix has become popular among health-conscious consumers who ...
(Date:1/24/2017)... ... January 23, 2017 , ... Texas Home ... acquisitions of two personal care service companies: Padre Home Health in Corpus Christi, ... 1, 2017. , Well regarded in their respective markets, these two agencies align ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017 The Pharmacy ... the implementation of the planned 2020 accredited education ... PTCB originally announced in 2013 that the requirement ... a road map of program changes designed to ... in the pharmacy. "We have ...
(Date:1/23/2017)... 2017  Therabron Therapeutics, Inc., a clinical-stage biotechnology ... respiratory care, today announced that the European Medicines ... granted Orphan Drug Designation for Therabron,s CG367 program, ... (BOS).  "We are pleased to have ... treat patients diagnosed with BOS following lung transplantation. ...
(Date:1/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The interventional radiology products market is expected to reach ... at a CAGR of 4.8%. This market is segmented based on ... the growth of this market are rising incidence of chronic diseases, ...
Breaking Medicine Technology: